Rhenman & Partners Asset Management’s Infinity Pharmaceuticals, Inc. INFI Stock Holding History

Rhenman & Partners Asset Management’s Portfolio INFI Stock Details INFI Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2014 Q4	–	Sell	-148,000	Closed	-$1.99M	–	97
2014 Q3	$1.99M	Buy	148,000 +34,727	+31%	+$414K	0.58%	72
2014 Q2	$1.44M	Sell	113,273 -19,493	-15%	-$203K	0.43%	75
2014 Q1	$1.09M	Sell	132,766 -77,234	-37%	-$1.04M	0.33%	79
2013 Q4	$2.9M	Buy	+210,000	New	+$2.97M	1.13%	28

Other funds holding INFI

OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return

Deerfield Management New York $8.48B AUM 99.04% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

BFA

BlackRock Fund Advisors San Francisco, California $542B AUM 18.14% 1-Year Est. Return

BB Biotech Schaffhausen, Switzerland $3.98B AUM 15.47% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

BIT

BlackRock Institutional Trust San Francisco, California $675B AUM 16.26% 1-Year Est. Return

Rhenman & Partners Asset Management's INFI Position: Q4 2014 in Review

Rhenman & Partners Asset Management sold out of Infinity Pharmaceuticals, Inc. (INFI) in Q4 2014, closing a stake of 148,000 shares — an estimated $1.99M sold.

Rhenman & Partners Asset Management first reported a position in INFI in Q4 2013 and held it in 4 quarters. The position peaked at $2.9M in Q4 2013. 143 funds tracked by Wall St. Rank hold INFI as of Q4 2014.

Rhenman & Partners Asset Management reported no remaining Infinity Pharmaceuticals, Inc. position as of Q4 2014 after selling out during the quarter.
Rhenman & Partners Asset Management sold 148,000 Infinity Pharmaceuticals, Inc. shares in Q4 2014, an estimated $1.99M.
Rhenman & Partners Asset Management first reported a position in Infinity Pharmaceuticals, Inc. in Q4 2013 and held it in 4 quarters.
Rhenman & Partners Asset Management's Infinity Pharmaceuticals, Inc. position peaked at $2.9M in Q4 2013.
143 funds tracked by Wall St. Rank held Infinity Pharmaceuticals, Inc. as of Q4 2014.

Based on Rhenman & Partners Asset Management's 13F filing for Q4 2014, filed 9 Feb 2015.